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A NUMBER of recent studies have shown
that the growth of certain rodent tumouirs
may beinhibited by the oraladministration
of the H-2 antagonist cimetidine (Gifford
et al., 1981; Osband et al., 1981). Further-
more, it has been proposed that the
antitumour effects of this compound are
due to its ability to inhibit histamine-
induced T-suppressor-cell activation (Os-
band et al., 1980a, 1981; Ogden & Hill,
1980; Gifford et al., 1981). In view of the
potential of this approach to immuno-
therapy we decided to undertake studies
on the effect of similar cimetidine proto-
cols on the growth of some of the experi-
mental rodent tumours routinely used in
our laboratories. The results of these
studies are summarized below.
Male syngeneic WAG/Ed (Edinburgh
University Centre for Laboratory Animals
strain of Wistar rats) were inoculated
s.c. with 105 viable cells of the asbestos-
induced mesothelioma MF3 (Bolton et al.,
in preparation) and cimetidine (Smith,
Kline and French Laboratories Ltd.,
Welwyn Garden City) was included in the
drinking water from the date of tumour
inoculation. Similarly, 105 or 106 viable
cells of the 3-methylcholanthrene (MCA)-
induced fibrosarcoma CCH1 (WAoodruff
et al., 1972) were inoculatedl s.c. into
syngeneic CBA/Ca mice, and cimetidine
included in the drinking water. In both
experiments, the concentrations of cimeti-
dine in the drinking water were such
that each animal received 100 mg/kg/day
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from the day of tumour inoculation.
Daily water consumption was recorded
for all animals on a cage basis for several
days before experiments to calculate the
mean. volume of water imbibed by each
mouse or rat. Control animals were
inoculated with tumour but received
unadulterated drinking water. Each cage
contained 4 to 5 animals. Tumour dia-
meters were measured at regular inter-
vals with vernier-scale calipers.
Spleen cells were prepared from syin-
geneic WAG/Ed rats, and the effect
of cimetidine on the in vitro binding of
histamine to spleen lymphocytes was
followed as described by Osband et al.
(1980b). Histamine dihydrochloride
(Sigma, Poole) was coupled to fluorescina-
ted bovine serum albumin (B.S.A., Sigma)
with 1-ethyl 3 (3-dimethylamino-propyl)
carbodiimide hydrochloride (Sigma) at
pH 5 6 using a method modlified from
Hannant et al. (1980).
The results of some of the in vivo
experiments are summarized in the Table.
They show that, at the concentration of
cimetidine used, there was no observable
effect on the incidence or size of tumour
in the rat and mouse models. The dose
of cimetidine used was the same as that
shown by Gifford et al. (1981) to have a
maximum inhibitory effect on the growth
of a syngeneic MCA-induced fibrosarcoma
in C3H mice and a lymphoma ascites of
C57BL/6 mice. The MCA-induced fibro-
sarcoma used in our study was syngeneic
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TABLE-Effect of oral cimetidine on the growth of rodent tumours*
Treatment
group
CCH1 control
CCH1 cimetidinet
MF3
MF3 cimetidine
Mean tumour4
diameter (mm +s.d.)
20-7+2-6
19-75+ 2-9
23-2+3 0
23-7+ 10 0
No. animals
with tumour
10/10
10/10
5/8
5/8
Days after tumour
inoculation
29
38
* Rats challenged with 105 cells; mice with 106 cells. Similar results, however, were obtained in mice
challenged with 105 cells.
t Cimetidine was included in the drinking water to give 100 mg/kg/day to each animal. It was assumed
that the fluid intake by each animal in the cage was similar. While this assumption is not entirely satisfactory,
within-group differences in tumour growth which might be attributed to differences in fluid intake of indivi-
dual mice were not obvious, as in most groups the growth rates were very constant.
I No difference in the growth rates of tumours between test and control groups was observed.
to CBA mice, and whilst the use of a
different mouse strain might have had
some effect, the complete absence of any
tumour inhibition is unlikely to be a
result of sub-optimal cimetidine con-
centration. Other studies (results not
presented) with tumour CCH1 showed
that concentrations of cimetidine up to
200 mg/kg/day also had no observable
effect. In contrast, Gifford et al. (1981)
found that tumour growth in mice was
sensitive to cimetidine concentrations
ranging from 15 to 200 mg/kg/day.
The lack of effect in the rat mesothe-
lioma experiments is not because cimeti-
dine does not function as a H-2-receptor
antagonist in this species. In vitro studies
clearly demonstrated that histamine
(labelled with fluorescinated BSA) was
able to bind specifically to 33-9 + 8 8%
(mean + s.d.) of normal WAG/Ed rat
spleen cells. Pretreatment of these cells
with 10-3M cimetidine for 1 h at 37°C
before washing and incubation with the
fluorescence reagent reduced the fluores-
cent staining to 12-1 + 2.7%. Therefore,
although cimetidine failed to influence
tumour growth, it did bind in vitro to
H-2 receptors on rat spleen cells.
In summary, cimetidine has been
shown to function as an H-2 receptor
antagonist in both mice and rats, and to
be an effective immunostimulator in
therapy of some tumours. However, it
appears that the compound may not
have universal application in tumour
therapy, because it can exhibit variable
effects on tumours within the same
species (mouse) and antitumour effects
in tumour-bearing rats have yet to be
demonstrated. Moreover, a recent report
suggests that cimetidine has no effect on
immunological parameters in man (Festen
et al., 1981). In the light of these observa-
tions we would suggest that further
studies with this compound are necessary
before any decision can be reached on its
suitability for clinical use.
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